Accreditation/Credit Designation
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Physicians’ Education Resource®, LLC, designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. EACCME® credits The UEMS-EACCME® and the AMA recognize each other’s CME credits since 2000. In 2014 the UEMS-EACCME® and the AMA renewed an agreement that European physicians can earn their ECMEC®s worldwide, except in Europe, that have been certified for AMA PRA Category 1 Credits™. For further information on reciprocity, please see the AMA website. Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Physicians’ Education Resource®, LLC, designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. EACCME® credits The UEMS-EACCME® and the AMA recognize each other’s CME credits since 2000. In 2014 the UEMS-EACCME® and the AMA renewed an agreement that European physicians can earn their ECMEC®s worldwide, except in Europe, that have been certified for AMA PRA Category 1 Credits™. For further information on reciprocity, please see the AMA website.Acknowledgment of Support
This activity is supported by an educational grant from Sanofi Genzyme.
A NEW WAVE OF PROGRESS IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: Global Perspectives on Antibody-Based Treatment Strategies
Release Date: August 31, 2021
Expiration Date: August 31, 2022
Activity Overview
This online, on-demand virtual symposium brings together renowned experts in myeloma to discuss the latest clinical data on novel monoclonal antibody therapies in MM. These experts use clinical case discussions and didactic lectures to provide insights the optimal strategies for treatment selection, and for combining and sequencing therapies throughout the disease continuum to improve patient outcomes.
This educational activity is an archive of the live virtual symposium held on July 28, 2021.
Acknowledgement of Commercial Support
This activity is supported by an educational grant from Sanofi Genzyme.
Instructions for This Activity and Receiving Credit
You may immediately download your certificate. |
Target Audience
These activities are intended for medical oncologists and hematologists who treat patients with MM. Fellows, nurses, nurse practitioners, physician assistants, and other health care professionals interested in the management of patients with MM are also invited to participate.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Distinguish the mechanism of action and the safety, and efficacy profiles of established and novel monoclonal antibodies for the treatment of MM
- Summarize data from recent combination trials investigating the role of monoclonal antibodies to treat relapsed/refractory MM
- Individualize therapeutic strategies for relapsed/refractory MM based on patient risk stratification, prior therapeutics regimens, and other clinical consideration
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible entities.
Faculty
Director of Clinical Research
Clinical Program Leader
Jerome Lipper Multiple Myeloma Center
Dana-Farber Cancer Institute
RJ Corman Professor of Medicine
Harvard Medical School
Boston, MA
Disclosures: Grant/Research Support: Oncopeptides, Celgene/BMS, Takeda, Karyopharm; Consultant: Oncopeptides, Celgene/BMS, Takeda, Karyopharm, Janssen, Sanofi, Secura Bio, GSK, Regeneron, AstraZeneca, Protocol Intelligence
Professor of Hematology
Director, Cord Blood Bank and Unrelated Donor Registry
Director, Hematology Clinical Trials Unit
Ankara University
Ankara, Turkey
Disclosures: Speaker’s Bureau: Amgen, Bristol Myers Squib, Sanofi, Janssen, Takeda, Oncopeptides
Consultant Haematologist NCCC
Newcastle Upon Tyne Hospital Trust
Professor of Clinical Haematology
University of Newcastle Upon Tyne
Newcastle Upon Tyne, England
Disclosures: Grant/Research Support: Bristol Myers Squibb, Takeda, Onyx; Consultant: Amgen, Bristol Myers Squibb, GlaxoSmithKline, Johnson & Johnson, Sanofi Genzyme, Takeda; Speakers’ Bureau: Amgen, Bristol Myers, Squibb, Johnson & Johnson, Sanofi Genzyme, Takeda
Deputy Director and Associate Professor
Department of Oncology, Hematology and Bone Marrow Transplantation
Department of Pneumology
University Medical Center Hamburg-Eppendorf
Hamburg, Germany
Disclosures: Grant Research Support: Amgen, Celgene, Janssen, Sanofi; Consultant: Adaptive Biotech, GlaxoSmithKline, Karyopharm Therapeutics, Roche, Takeda, AbbVie
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
Login or Register to Start Activity
Please use the form below to Register or Log In to begin Activity.
